checkAd

     141  0 Kommentare Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies

    Regulatory News:

    Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies (CI2024) taking place on July 10-13, 2024, in Vancouver, Canada.

    On this occasion, Professor Stephen O'Leary, M.D., Ph.D., will present the results of the Phase 2a clinical trial of SENS-401 in the prevention of residual hearing loss after cochlear implantation, of which he is the principal investigator. The study is developed in collaboration with partner Cochlear Limited, the global leader in implantable hearing devices.

    The presentation will take place on Saturday, July 13, 2024, at 9.40am (PDT) at the Vancouver Convention Centre.

    Practical details

    Presentation by Stephen O’LEARY, M.D., Ph.D.: Early Preservation of Residual Hearing Six Weeks Post Cochlear Nucleus CI622 Implantation and Detection of SENS-401 in Perilymph: Findings from a Phase IIa Clinical Trial Investigating Repeated Oral Administration of SENS-401 in Implant Patients

    Address: 1055 Canada Place, Vancouver, British Columbia

    In 2017, Sensorion and Cochlear signed a research collaboration agreement on SENS-401, under which Cochlear has an option, exercisable once the data of the complete readout of this study is available, to negotiate with Sensorion the rights for a global license to distribute SENS-401 for applications and uses related to certain implantable devices.

    About SENS-401
    SENS-401 (Arazasetron), Sensorion’s clinical stage lead drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion currently develops SENS-401 in a Phase 2a for the prevention of residual hearing loss in patients scheduled for cochlear implantation and in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the U.S. for the prevention of platinum-induced ototoxicity in pediatric population.

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces …

    Schreibe Deinen Kommentar

    Disclaimer